FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
 Annual Meeting - EconoTimes)
SEOUL, South Korea, May 15, 2017 -- ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, presented results from a study highlighting the use of CRISPR/Cas9 nucleases for specific and efficient genome editing in human primary T-cells, without causing severe cell damage and growth retardation in a poster presentation at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting being held in Washington, DC from May 10-13, 2017.
The poster presentation entitled “Genome editing of human T cells to generate CAR-T cells with enhanced antitumor function” aimed to study the proposed idea that T-cell anergy serves to induce dysfunction in a wide variety of tumor microenvironments. Using CRISPR/Cas9-mediated gene editing, the researchers were able to successfully knock out DGKα, a tolerance-associated gene at an 80% efficiency rate, which allowed T-cells to reverse hypofunction induced by anergy. Based on this result, the researchers combined the lentiviral delivery of CAR and the electroporation of RNP to generate a CRISPR gene-edited CAR-T cell. These edited CAR-T cells demonstrated lower sensitivity to immunosuppressive conditions and were hyper-responsive against tumor cells.
“We are honored to be recognized by ASGCT for our work using CRISPR/Cas9-mediated gene editing,” commented Seokjoong Kim, Research Director at Toolgen. “The data presented in the poster presentation demonstrates preliminary success in utilizing CRISPR/Cas9 nucleases for specific and efficient gene editing in human primary T-cells. The findings suggest that CAR and TCR T cells with a disrupted anergy-related gene may be potent effector cells against various cancers. We believe that these results continue to validate our approach to gene editing and provide support for further research to move our pipeline of opportunities into the clinic.”
The authors of the presentation were Yoon-Young Kim, In Young Jung, Ho Sung Yu1, Seokjoong Kim, R&D Center, Toolgen, Inc., Seoul, South Korea
About ToolGen, Inc.
ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies. It creates, and holds intellectual property rights for essential tools and technologies for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of our innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit www.toolgen.com.
Investor Relations Contact The Ruth Group Tram Bui / Alexander Lobo Phone: 646-536-7035 / 7037 [email protected] [email protected]
